Strongbridge Biopharma

Strongbridge Biopharma’s primary focus has been to build its franchise around rare endocrine disorders, which includes product candidates for the treatment of endogenous Cushing’s syndrome and acromegaly, two rare diseases with a high unmet need for innovative treatment options. Given the well-identified and concentrated prescriber base addressing its target markets, the Company intends to use a small, focused sales force to market its products, if approved, in the United States, European Union and other key global markets. The Company intends to identify and in-license or acquire products or product candidates that would be complementary to its existing rare endocrine franchise or that would form the basis for new rare disease franchises.

Strongbridge Biopharma plc (SBBP) Management on Q1 2020 Results - Earnings Call Transcript

Strongbridge Biopharma (SBBP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Strongbridge Biopharma (SBBP) Report Negative Earnings Next Week? What You Should Know

DUBLIN, Ireland and TREVOSE, Pa., Feb.  27, 2020  (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that John H. Johnson, executive chairman, and Robert Lutz, chief financial officer, will present at the Cowen and Company 40th Annual Healthcare Conference on Monday, March 2, at 4:50 pm ET.  The conference is being held at the Boston Marriott Copley Place in Boston, MA. In addition to the presentation, the Company will host a breakout session at 5:25 pm ET, immediately following the presentation.

Strongbridge Biopharma plc to Present at the Cowen and Company 40th Annual Healthcare Conference

Strongbridge Biopharma plc (SBBP) Q4 2019 Results - Earnings Call Transcript

Strongbridge Biopharma: A Big Opportunity For Cushing's Syndrome Patients And For Investors

~ Expects to Report KEVEYIS®(dichlorphenamide) Fourth Quarter 2019 Revenue of Approximately $5.6 Million and Full-Year 2019 Revenue of Approximately $21.7 Million, a 29 Percent Increase over 2018 Revenue of $16.8 Million ~

Strongbridge Biopharma plc Announces Preliminary Fourth Quarter and Full-Year 2019 Financial Results and Provides Update on Corporate Priorities

The fall in the stock price has created a compelling 'sum of the parts' valuation story and shares have stabilized recently.

Sifting Through The Story At Strongbridge Biopharma

~ The Company Remains Focused on Completing the LOGICS Study and Submitting a New Drug Application (NDA) for RECORLEV™ (levoketoconazole), While Ensuring Continued Growth and Profitability of KEVEYIS® (dichlorphenamide) and Serving the Unmet Needs of the Primary Periodic Paralysis Community ~

Strongbridge Biopharma plc Announces Additional Steps to Improve Operational Efficiencies and Appoints New Lead Independent Director

Strongbridge Biopharma plc (SBBP) Q3 2019 Results - Earnings Call Transcript

DUBLIN, Ireland and TREVOSE, Pa., Nov.  05, 2019  (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that Matthew Pauls is stepping down as president, chief executive officer (CEO) and director, effective immediately. The Board of Directors (Board) and Mr. Pauls have mutually agreed that now is the right time to transition leadership of the Company.

Strongbridge Biopharma plc Announces CEO Transition Plan and Provides Preliminary Third Quarter 2019 Financial Results and Corporate Updates

Strongbridge Biopharma (SBBP) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Will Strongbridge Biopharma (SBBP) Report Negative Q3 Earnings? What You Should Know

DUBLIN, Ireland and TREVOSE, Pa., Oct.  17, 2019  (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that long-term efficacy and safety characterization results for KEVEYIS® (dichlorphenamide), the first and only U.S. Food and Drug Administration (FDA) approved treatment for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP), will be presented at the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting held from October 16 – 19, 2019 in Austin, Texas. 

Strongbridge Biopharma plc Presents KEVEYIS® (dichlorphenamide) Primary Periodic Paralysis (PPP) Data at the 2019 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting

DUBLIN, Ireland and TREVOSE, Pa., Sept.  25, 2019  (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that Matthew Pauls, president and chief executive officer, will present at the 2019 Cantor Global Healthcare Conference.  The details of the conferences are as follows:

Strongbridge Biopharma plc to Present at the 2019 Cantor Global Healthcare Conference

~ RECORLEV Resulted in Sustained Improvements in Urinary Free Cortisol (UFC) and Provided Clinical Benefit, As Demonstrated By Improvements in Comorbidities and Characteristic Signs and Symptoms of Cushing’s Syndrome ~

Strongbridge Biopharma plc Announces RECORLEV™ (levoketoconazole) Phase 3 SONICS Data Published in The Lancet Diabetes & Endocrinology

DUBLIN, Ireland and TREVOSE, Pa., Sept.  03, 2019  (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that Matthew Pauls, president and chief executive officer, will present at the H.C. Wainwright 21st Annual Global Investment Conference and the Janney Montgomery Scott Healthcare Conference 2019.  The details of the conferences are as follows:

Strongbridge Biopharma plc to Present at the H.C. Wainwright 21st Annual Global Investment Conference and the Janney Montgomery Scott Healthcare Conference 2019

Strongbridge Biopharma's (SBBP) CEO Matthew Pauls on Q2 2019 Results - Earnings Call Transcript

Strongbridge Biopharma has a promising clinical pipeline for the metabolic disease Cushing’s syndrome.

Strongbridge And Recorlev In Endogenous Cushing's Syndrome: Potential Impact On Liver Steatosis

Strongbridge Biopharma (SBBP) delivered earnings and revenue surprises of 26.47% and -7.48%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Strongbridge Biopharma (SBBP) Reports Q1 Loss, Lags Revenue Estimates

Strongbridge Biopharma PLC (SBBP) CEO Matthew Pauls on Q1 2019 Results - Earnings Call Transcript

Amarin Corporation Plc

AstraZeneca

Jazz Pharmaceuticals

Ligand Pharmaceuticals

Leap Therapeutics

Lexicon Pharmaceuticals

PhaseBio Pharmaceuticals Inc

Roche Holding AG

SAGE Therapeutics

Sanofi

Biotech stocks had an upweek, with the release of clinical trial results and the positive broader market sentiment offering ample support.

News for Strongbridge Biopharma Stock (SBBP)